JOINTstat™ measures a specific protein in blood,
which is often present in people with RA.
JOINTstat™ provides your doctor with biological information to support his/her clinical assessment of your RA.
Studies to date have shown that 14-3-3η:
- When positive (>0.19 ng/ml), provides a 5-50 times greater likelihood of having RA versus non-RA.
- Is involved in driving RA by increasing the levels of harmful inflammation and joint damage factors; less 14-3-3η is better.
- Is positive in patients with joint pain who develop RA within 5 years of symptom onset.
- At high levels (>0.80 ng/ml) is an indicator of RA that will lead to more joint damage over 3 years.
- At lower levels (<0.40 ng/ml or negative in RA diagnosed patients) is an indicator of a higher likelihood of response to RA therapy.
- Decreasing levels with treatment or over time, indicate a favorable response and outcome.
- Overall, patients who are negative or who have low levels (<0.40 ng/ml) have a more favorable outcome.